The bi-specific anti-CD3/CD19 monoclonal antibody blinatumomab has been associated with remission in patients with BCR::ABL1-positive ALL when given in combination with dasatinib and glucocorticoids [92]. Here, CD19 is linked to acute lymphoblastic leukemia.